L 8 Diploma Ortho and Corona - Tagged
Orthomyxoviridae Overview
Definition: Greek origin "myxa" meaning mucus
Members:
Influenza A: Causes pandemics and epidemics, infects humans and animals (e.g., birds, pigs)
Influenza B: Causes epidemics, infects only humans
Influenza C: Causes mild upper respiratory tract infections
Structure and Genome
Type: Negative-sense single-stranded RNA (-ve ssRNA)
Configuration:
Enveloped
Segmented genome with 8 segments
10-11 proteins produced
Requires RNA polymerase (RNA pol) to infect host
Important Proteins
Hemagglutinin (HA):
Function: Binds to sialic acid, aids in fusion and entry, targeted for vaccine development
Neuraminidase (NA):
Function: Cleaves sialic acid for virus release and spread, targets for antiviral medications (Oseltamivir, Zanamivir)
M2 Protein:
Function: Acts as a proton pump, essential for uncoating of the virus, targeted by older antivirals (Amantadine) which are now less effective due to resistance
Viral Lifecycle
Entry: HA binds to sialic acid → endocytosis
Replication: occurs in the nucleus, utilizes host machinery, steals 5' cap from host mRNA to initiate transcription
Release: Virus buds from the plasma membrane acquiring HA and NA proteins to form a complete virus
Antigenic Changes
Antigenic Drift:
Results from errors in RNA polymerase during genome replication, contributes to seasonal flu
Affects both type A and B viruses
Antigenic Shift:
Involves genetic reassortment, occurs only in type A due to its segmented genome and ability to infect multiple host species
Associated with pandemic outbreaks
Historical Examples
2009 H1N1 Pandemic:
Triple reassortment virus, resistant to Amantadine and Rimantadine
Highlight of the importance of understanding genetic shifts in virus evolution
Influenza Pandemics Timeline:
Key occurrences include: 1918 H1N1, 1957 H2N2, 1968 H3N2, 2009 H1N1 (swine flu)
Pathogenicity and Symptoms
Infection Sites: Upper and lower respiratory tracts
Destroys mucus-secreting and ciliated cells, leading to increased susceptibility to secondary bacterial infections
Symptoms: Abrupt onset (1-4 days incubating) including fever, cough, body aches, fatigue, vomiting and diarrhea (more common in children)
Immune Response
Interferon and Cytokine Response: Crucial for controlling infection
Strain Specificity: Immunity against HA and NA is strain-specific; reinfections with different strains are common
Treatment and Vaccination
Antiviral Medications: Oseltamivir and Zanamivir inhibit NA, must be used early
Vaccination: Includes inactivated vaccines (grown in eggs) and live attenuated vaccines (cold-adapted)
Annual Vaccinations Recommended: All individuals encouraged to vaccinate due to widespread impact on health
Laboratory Diagnosis
Tests include cell culture, Hemagglutination tests for virus presence, Serology, and RT-PCR for strain identification
Risk Populations
High-risk groups: Elderly, young children, immunocompromised, pregnant women
Annual mortality in the U.S. ranges from 3,000 to 49,000
Conclusion on Influenza
Influenza virus poses significant public health issues due to its capacity for rapid mutation and reassortment, leading to seasonal outbreaks and sporadic pandemics.